Compare Automatic Data Processing Inc (ADP) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Automatic Data Processing Inc vs Adaptive Biotechnologies Corp — how do they compare? Automatic Data Processing Inc trades at $241.65 (market cap $98.17B), while Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B). The key difference: Automatic Data Processing Inc is far larger — about 29.5× Adaptive Biotechnologies Corp's market cap, and Automatic Data Processing Inc pays a 2.77% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADP | ADPT | |
|---|---|---|
Market Cap | $98.17B | $3.33B |
Sector | Industrials | Health |
52-Week High | $310.94 | $22.37 |
52-Week Low | $188.79 | $10.24 |
Enterprise Value | $99.24B | $3.19B |
Dividend Yield | 2.77% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
